Lonza Group To Acquire A U.S. Clinical Manufacturing Site To Support Ongoing Customer Demand

Published: Oct 03, 2017

Lonza to Acquire a U.S. Clinical Manufacturing Site to Support Ongoing Customer Demand

• Site is being acquired from Shire plc and adds early-phase clinical manufacture on the West Coast
• Capacity includes 1,000L and 2,000L single-use bioreactors, all associated media & buffer prep and downstream purification capabilities
• Facility will complement existing clinical assets in Slough (UK) and enhance Lonza’s capability to support its customers’ products throughout their lifecycle
• All 100+ former Shire site personnel will have opportunity to continue in their role with Lonza

Basel, Switzerland, 3 October 2017 – Lonza announced today that it is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire plc. Financial details of the deal were not disclosed.

The 58,000-square-foot (approximately 5,388-square-meter) site, located in Hayward, CA (USA), has been operating as a multiproduct cGMP facility since 1990 and has a successful regulatory track record. Assets include 1,000L and 2,000L single-use bioreactors and associated downstream capabilities. Currently the site employs more than 100 personnel, all of whom will have the opportunity to continue in their role with Lonza.

In response to Lonza’s Pharma&Biotech customers’ increasing demand for clinical-stage manufacturing capacity, the acquisition of the site will provide additional cGMP capacity and will supplement our existing assets in Slough (UK). Lonza customer batches will be initiated in 2018.

“As a committed partner to the pharmaceutical and biotechnology industry, Lonza recognizes the need for established and dependable global manufacturing facilities,” said Karen Fallen, Vice President, Business Unit Head, Clinical Development, for Lonza. "The acquisition of this site allows our customers greater access to clinical capacity from a U.S. site. The additional capacity will support the needs of our customers to secure manufacture for their products’ complete lifecycle across Lonza’s global manufacturing network."

“We are confident in Lonza’s ability to continue the important work happening in Hayward and are pleased that they recognized the talent of the team already in place,” said Matt Walker, Shire’s Head of Technical Operations. “Moving forward, Lonza will serve as a partner to Shire, managing the manufacture and supply of reagents used in a number of Shire products.”

About Lonza

Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the Lonza group provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at www.lonza.com.

Lonza Contact Details

Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com

Dominik Werner, Head Corporate Communications
Lonza Group Ltd
Tel +41 61 316 8798
dominik.werner@lonza.com

Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com

Shire Contact Details
Katie Joyce, Head of U.S. Corporate Affairs and Media Relations
Shire plc
Tel +1 617 678 9370
KJoyce@Shire.com

Back to news